Clementia is a privately held clinical-stage biopharmaceutical company focused on bringing effective new treatments to people who have none.
Our team has a proven track record of developing and commercializing orphan drugs. We are rapidly developing our lead product candidate, palovarotene, an investigational therapy for the treatment of fibrodysplasia ossificans progressiva (FOP) and other diseases.
From our inception through March 31, 2017, we have received gross proceeds of $102.8 million from such transactions, of which $102.2 million was in the form of gross proceeds from the sale of preferred shares, $0.5 million was in the form of gross proceeds from the sale of convertible notes and $0.1 million was in the form of gross proceeds from the sale of common shares.
For further information, please contact: firstname.lastname@example.org